Point72 Asia (Singapore) Pte. Ltd. Crinetics Pharmaceuticals, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 12,889 shares of CRNX stock, worth $549,973. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,889Holding current value
$549,973% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
248Shares Held
93.6MCall Options Held
695KPut Options Held
80.6K-
Vanguard Group Inc Valley Forge, PA9.17MShares$391 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$358 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$277 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$266 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$246 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.29B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...